The aspect of Pfizer's coronavirus vaccine that really stunned the company's scientists was the fact that vaccinated participants in the Phase 3 efficacy trial had protections against the pathogen by day 12, a time at which there was barely any antibody response, Stat News reports. "That was the biggest surprise," said Vidia Roopchand, Pfizer's principal scientist for viral vaccines.
Roopchand is still trying to figure exactly why that is — not that it's a bad thing — by poring over the data. One possibility is that other aspects of the immune system such as T-cells that Roopchand says have largely been neglected in immunology research may have played a significant role. It's possible, he suggested, that's more important to measure cellular immunity than look for a robust antibody response. "The 12-day protection data is telling us there's more to it," Roopchand told Stat. "This is a great time to learn."
He also indicated that the discovery could affect future vaccine development, regardless of the virus. Before, vaccine candidates would likely get tossed to the side if they didn't produce a strong antibody response in animal testing, but a deeper look at the rest of the immune system could change that approach. Read more at Stat News.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Employees are branching out rather than moving up with career minimalismThe explainer From career ladder to lily pad
-
‘It is their greed and the pollution from their products that hurt consumers’Instant Opinion Opinion, comment and editorials of the day
-
Jane Austen lives on at these timeless hotelsThe Week Recommends Here’s where to celebrate the writing legend’s 250th birthday
-
Vaccine critic quietly named CDC’s No. 2 officialSpeed Read Dr. Ralph Abraham joins another prominent vaccine critic, HHS Secretary Robert F. Kennedy Jr.
-
This flu season could be worse than usualIn the spotlight A new subvariant is infecting several countries
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
